Antibiotics Top List Of New Exclusivity Benefits In Draft Cures Legislation
This article was originally published in The Pink Sheet Daily
Executive Summary
Sponsors could transfer or sell some QIDP exclusivity to other products under draft bill, which also offers new exclusivity perks for orphan drugs, 505(b)(2) applications, ANDAs and biosimilars – but GPhA isn’t happy.